ARLINGTON, Va.--(BUSINESS WIRE)--
CACI International Inc (NYSE:CACI) announced today that it was awarded a blanket purchase agreement (BPA) to provide support services to the Drug Enforcement Administration (DEA). This BPA represents continuing work for CACI in its Business Systems market area.
The DEA enforces the controlled substances laws and regulations of the United States, and recommends and supports non-enforcement programs aimed at reducing the availability of illicit controlled substances. Under this BPA, CACI will support DEA’s enforcement and demand reduction mission, both domestically and internationally, with onsite financial and acquisition management system support; system administration and development for DEA’s financial data warehouse system and internal intranet sites; travel system project management, analysis, and training; and financial policy support. CACI will also support the development and implementation of new and improved business systems and operating procedures to help to ensure DEA’s continued success in complying with federal financial and acquisition management laws, regulations, and policies.
DeEtte Gray, President of U.S. Operations, said, “This award demonstrates CACI’s proven solutions and services for financial, acquisition, and property support areas. We are proud to continue our work with this important customer, delivering successful enterprise business system services that support the men and women of the DEA who enforce our nation’s controlled substances laws.”
CACI provides information solutions and services in support of national security missions and government transformation for Intelligence, Defense, and Federal Civilian customers. CACI is a member of the Fortune 1000 Largest Companies, the Russell 2000 Index, and the S&P SmallCap600 Index. CACI’s sustained commitment to ethics and integrity defines its corporate culture and drives its success. With approximately 18,600 employees worldwide, CACI provides dynamic career opportunities for military veterans and industry professionals to support the nation’s most critical missions. Join us! www.caci.com.
There are statements made herein which do not address historical facts, and therefore could be interpreted to be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors that could cause actual results to differ materially from anticipated results. The factors that could cause actual results to differ materially from those anticipated include, but are not limited to, the risk factors set forth in CACI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017, and other such filings that CACI makes with the Securities and Exchange Commission from time to time. Any forward-looking statements should not be unduly relied upon and only speak as of the date hereof. These statements are not to be construed as an endorsement by the Drug Enforcement Administration.
CACI-Awards
View source version on businesswire.com: http://www.businesswire.com/news/home/20171221005058/en/
